U

University of Ottawa | University of Ottawa Heart Institute - Lipid Clinic

Research site

(Unclaimed)

Location

40 Ruskin St Room H4203, Ottawa, Ontario, Canada

Site insights

Top conditions

Top treatments

Rivaroxaban

Warfarin

VX-670

Capecitabine

enalapril

ZW25

hydralazine

Nitric Oxide

AOC 1020

Vinorelbine

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 71 total trials

Locations recently updated

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) (Galileo)

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple d...

Enrolling

Myotonic Dystrophy Type 1 (DM1)

Drug: Placebo

Drug: VX-670

A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema (Meerkat)

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

Active, not recruiting

Uveitic Macular Edema

Other: Sham

Drug: Vamikibart

Phase 1/2 Study of AOC 1020 in Adults With Facioscapulohumeral Muscular Dystrophy (FSHD) (FORTITUDE)

A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Explora...

Enrolling

Muscular Dystrophy, Landouzy Dejerine

Fascioscapulohumeral Muscular Dystrophy

Drug: AOC 1020

Drug: Placebo

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA)

The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and...

Active, not recruiting

AML

Bone Marrow Transplant

Drug: Conventional Care

Drug: Iomab-B

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with s...

Active, not recruiting

HER2-expressing Cancers

Drug: Capecitabine

Drug: ZW25 (Zanidatamab)